Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

305 results found

2025 ∙ SAGE

SAGE Evidence to Recommendation Framework: Extended-valency PCVs

  • Evidence to recommendation table
  • Pneumococcal disease
Download:
2025 ∙ SAGE

Meeting of the Strategic Advisory Group of Experts on Immunization, March 2025: Conclusions and recommendations

  • Meeting report
  • Pneumococcal disease
  • Mpox
  • Herpes zoster
  • Poliomyelitis
Download:
2024 ∙ Silverii, G. A. Gabutti, G. Tafuri, S. Sarti, F. Pratesi, A. Clerico, A. Fornengo, R. Greco, C. Irace, C. Sordi, V. Sorice, G. P. Cavallo, M. Ponziani, M. C. Mannucci, E. Dicembrini, I.

Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies

  • Adults
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
High
2024 ∙ Gebreyesus, A. Tesfay, K.

Effect of maternal education on completing childhood vaccination in Ethiopia: systematic review and meta-analysis

  • Africa
  • Ethiopia
  • Children
  • Tuberculosis
  • Poliomyelitis
  • Diphtheria
  • Tetanus
  • Hepatitis B
  • Haemophilus influenzae type B
  • Pneumococcal disease
  • Measles
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2024 ∙ Sepúlveda-Pachón, I. T. Dunne, E. M. Hanquet, G. Baay, M. Menon, S. Jodar, L. Gessner, B. D. Theilacker, C.

Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review

  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Moderate
2024 ∙ Grant, L. R. Hanquet, G. Sepulveda-Pachon, I. T. Theilacker, C. Baay, M. Slack, M. P. E. Jodar, L. Gessner, B. D.

Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance

  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Wagner, G. Gartlehner, G. Thaler, K. Ledinger, D. Feyertag, J. Klerings, I. Saif-Ur-Rahman, K. M. Devane, D. Olsson, K. Adel Ali, K. Vygen-Bonnet, S. Salo, H. Zavadska, D. Grgic Vitek, M. Oona, M. Cunney, R. Tuerlinckx, D. Kristensen Lomholt, F. Sommer, I.

Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis

  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Moderate
2024 ∙ Feng, S. McLellan, J. Pidduck, N. Roberts, N. Higgins, J. P. Choi, Y. Izu, A. Jit, M. Madhi, S. A. Mulholland, K. Pollard, A. J. Procter, S. Temple, B. Voysey, M.

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Beetch, J. E. Janitz, A. Beebe, L. A. Gowin, M. Xu, C. Clifton, S. Kuhn, K. G.

Indirect Effects of the COVID-19 Pandemic on Routine Childhood Vaccination in Low-Income Countries: A Systematic Review to Set the Scope for Future Pandemics

  • Newborn
  • Children
  • Adolescents
  • Low and Middle Income Countries
  • Tuberculosis
  • Poliomyelitis
  • Diphtheria
  • Pertussis
  • Tetanus
  • Hepatitis B
  • Haemophilus influenzae type B
  • Pneumococcal disease
  • Rotavirus
  • Measles
  • Rubella
  • Malaria
  • Yellow fever
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2024 ∙ Besteman, S. B. Bogaert, D. Bont, L. Mejias, A. Ramilo, O. Weinberger, D. M. Dagan, R.

Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review

  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
Loading...